异甘草酸镁联合生长抑素治疗肝硬化的临床观察

Clinical observation of magnesium isoglycyrrhizinate combined with somatostatin in treatment of liver cirrhosis

目的探讨异苷草酸镁联合生长抑素治疗肝硬化患者的临床疗效。方法选取2016年1月-2019年6月郑州市第七人民医院收治的120例肝硬化患者作为研究对象,根据不同治疗方法将患者分为对照组和观察组,每组各60例。对照组采取注射用生长抑素治疗,将6 mg加入到48 mL的0.9%NaCl注射液中,以0.25 mg/h速度连续静脉滴注。观察组在对照组患者治疗基础上静脉滴注异甘草酸镁注射液,0.1 g以10%葡萄糖注射液250 mL稀释,1次/d。两组均连续治疗4周。观察两组患者的临床疗效,同时比较两组的肝功能指标和并发症发生情况。结果治疗后,观察组的治疗总有效率为90.0%明显高于对照组的60.0%(P<0.05)。治疗后,两组总胆红素(TB)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转氨酶(AST)、碱性磷酸酶(ALP)水平均明显低于治疗前(P<0.05),且观察组各项肝功能指标明显低于对照组(P<0.05)。治疗后,观察组的各并发症发生率低于对照组,其中消化道出血发生率明显低于对照组(P<0.05)。结论异苷草酸镁联合生长抑素治疗肝硬化可有效改善患者肝功能,可降低上消化道出血等并发症发生率,疗效显著,明显优于单一生长抑素治疗,且安全性高,具有临床推广应用价值。

Objective To investigate the effects of magnesium isoglycyrrhizinate combined with somatostatin on patients with liver cirrhosis. Methods Patients(120 cases) with liver cirrhosis in the Seventh People’s Hospital of Zhengzhou from January 2016 to June 2019 were enrolled. According to different treatment methods, they were divided into control and observation group, and each group had 60 cases. Patients in the control group were treated with Somatostatin for Injection, 6 mg was added to 0.9% 48 mL NaCl injection, and continuous intravenous infusion was performed at the rate of 0.25 mg/h. Patients in the observation group were iv administered with Magnesium Isoglycyrrhizinate Injection on the basis of control group, 0.1 g was diluted with 250 mL 10% glucose injection, once daily. Patients in two groups were treated for 4 weeks. The clinical efficacy in two groups were observed, and the liver function indexes, and the incidence of complications in two groups were compared. Results After treatment, the total effective rate in the observation group was 90.0%, which was significantly higher than 60.0% of the control group(P < 0.05). After treatment,the levels of TB, ALT, AST, and ALP were lower than those before treatment(P < 0.05), and the liver function indexes in the observation group were significantly lower than those in the control group(P < 0.05). After treatment, the incidence of complications in the observation group was lower than that in the control group, and the incidence of gastrointestinal bleeding was significantly lower than that in the control group(P < 0.05). Conclusion Magnesium isoglycyrrhizinate combined with somatostatin in treatment of liver cirrhosis can effectively improve the liver function of patients, and reduce the incidence of complications such as upper digestive tract bleeding. The treatment has significant efficacy, is significantly better than single somatostatin treatment,with high safety. Therefore, it has clinical application value.